Skip to main content
SpringerLink
Log in

New treatment-induced adverse effects we need to learn as modern hepatologists

  • Invited Commentary
  • Published:
Hepatology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int. 2019. https://doi.org/10.1007/s12072-018-9921-7

  2. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52(4):512–519

    Article  CAS  PubMed  Google Scholar 

  3. Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 2017;52(4):494–503

    Article  CAS  PubMed  Google Scholar 

  4. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11(4):317–370

    Article  PubMed  Google Scholar 

  5. Kudo M. Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer 2018;7(1):20–27

    Article  PubMed  PubMed Central  Google Scholar 

  6. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492–2502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19(7):940–952

    Article  PubMed  Google Scholar 

  8. Nadeau BA, Fecher LA, Owens SR, Razumilava N. Liver toxicity with cancer checkpoint inhibitor therapy. Semin Liver Dis 2018;38(4):366–378

    Article  CAS  PubMed  Google Scholar 

  9. Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, et al. Incidence of grade 3–4 liver injury under immune checkpoints inhibitors: a retrospective study. J Hepatol 2018;69(6):1396–1397

    Article  PubMed  Google Scholar 

  10. Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2018;41(8):760–765

    Article  CAS  PubMed  Google Scholar 

  11. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714–1768

    Article  CAS  PubMed  Google Scholar 

  12. Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol Res 2018;48(8):622–634

    Article  CAS  PubMed  Google Scholar 

  13. De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68(6):1181–1190

    Article  CAS  PubMed  Google Scholar 

  14. Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 2018;38(6):976–987

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Faculty of Medicine Yamagata University, 2-2-2 Iidanishi, Yamagata, 9909585, Japan

    Yoshiyuki Ueno

Authors
  1. Yoshiyuki Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiyuki Ueno.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ueno, Y. New treatment-induced adverse effects we need to learn as modern hepatologists. Hepatol Int 13, 391–394 (2019). https://doi.org/10.1007/s12072-019-09947-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-019-09947-2

Keywords

Search

Navigation